Arrowhead Pharmaceuticals reported earnings of -$ 3.04 per ARWR share on Nov 12, 2026, beating analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 1.52 |
| Earnings Per Share (Surprise) | -$ 3.04 (-$ 1.52) |
| Last Year's EPS | $ 0.3825 |
| EPS YoY Change |
Out of the last 100 earnings reporting periods, Arrowhead Pharmaceuticals beat analysts’ expectations 19 times and fell short of expectations 35 time(s). Arrowhead Pharmaceuticals reported earnings per share of -$ 3.04 in the last report falling to reach an estimated EPS of -$ 1.52 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 1.52 | -$ 3.04 | -$ 0.18 | |
| Aug 4, 2026 | -$ 1.28 | -$ 1.36 | -$ 1.26 | |
| May 7, 2026 | -$ 1.09 | -$ 0.93 | $ 2.75 | |
| Feb 5, 2026 | $ 0.60 | $ 0.22 | -$ 1.39 | |
| Nov 25, 2025 | -$ 0.11 | -$ 0.18 | -$ 1.38 | |
| Aug 7, 2025 | -$ 0.94 | -$ 1.26 | -$ 1.38 | |
| May 12, 2025 | -$ 0.06 | $ 2.75 | -$ 1.02 | |
| Feb 10, 2025 | -$ 0.42 | -$ 1.39 | -$ 1.24 | |
| Nov 26, 2024 | -$ 1.05 | -$ 1.38 | -$ 1.03 | |
| Aug 8, 2024 | -$ 0.58 | -$ 1.38 | -$ 0.96 | |
| May 9, 2024 | -$ 0.06 | -$ 1.02 | $ 0.45 | |
| Feb 6, 2024 | -$ 0.78 | -$ 1.24 | -$ 0.39 | |
| Nov 29, 2023 | -$ 0.70 | -$ 1.03 | -$ 0.81 | |
| Aug 7, 2023 | -$ 0.58 | -$ 0.96 | -$ 0.68 | |
| May 2, 2023 | -$ 0.64 | $ 0.45 | $ 0.41 | |
| Feb 6, 2023 | $ 1.14 | -$ 0.39 | -$ 0.60 | |
| Nov 28, 2022 | -$ 0.57 | -$ 0.81 | -$ 0.61 | |
| Aug 4, 2022 | -$ 0.45 | -$ 0.68 | -$ 0.29 | |
| May 10, 2022 | -$ 0.08 | $ 0.41 | -$ 0.26 | |
| Feb 2, 2022 | -$ 0.22 | -$ 0.60 | -$ 0.20 |
Arrowhead Pharmaceuticals’s stock was trading at $ 49.36 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, ARWR’s price decreased to $ 47.78 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 3.04 | $ 49.36 | $ 47.78 | |
| Aug 4, 2026 | -$ 1.36 | $ 86.01 | $ 86.91 | |
| May 7, 2026 | -$ 0.93 | $ 79.14 | $ 72.69 | |
| Feb 5, 2026 | $ 0.22 | $ 68.06 | $ 64.52 | |
| Nov 25, 2025 | -$ 0.18 | $ 44.26 | $ 57.71 | |
| Aug 7, 2025 | -$ 1.26 | $ 16.31 | $ 16.42 | |
| May 12, 2025 | $ 2.75 | $ 13.03 | $ 15.28 | |
| Feb 10, 2025 | -$ 1.39 | $ 20.24 | $ 18.89 | |
| Nov 26, 2024 | -$ 1.38 | $ 18.79 | $ 26.15 | |
| Aug 8, 2024 | -$ 1.38 | $ 25.00 | $ 23.41 | |
| May 9, 2024 | -$ 1.02 | $ 25.22 | $ 22.08 | |
| Feb 6, 2024 | -$ 1.24 | $ 32.02 | $ 31.65 | |
| Nov 29, 2023 | -$ 1.03 | $ 28.92 | $ 21.20 | |
| Aug 7, 2023 | -$ 0.96 | $ 31.65 | $ 27.49 | |
| May 2, 2023 | $ 0.45 | $ 35.72 | $ 40.20 | |
| Feb 6, 2023 | -$ 0.39 | $ 36.74 | $ 33.62 | |
| Nov 28, 2022 | -$ 0.81 | $ 29.50 | $ 29.99 | |
| Aug 4, 2022 | -$ 0.68 | $ 44.36 | $ 45.96 | |
| May 10, 2022 | $ 0.41 | $ 32.72 | $ 28.95 | |
| Feb 2, 2022 | -$ 0.60 | $ 55.10 | $ 48.99 |
Arrowhead Pharmaceuticals released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Arrowhead Pharmaceuticals missed analysts’ expectations during the last earnings period by
